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Sclinical outcomes amongst the subgroups. Two years data of the full cohort will be
available upon presentation.
Conclusions: The Energy demonstrates very good results which were promising for
subgroups with diabetes, small vessels and even acute coronary syndrome. Utility of
such modern bare metal stent platforms is still relevant in the era of drug-eluting
stents.TCT-184
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Background: Late adverse events such as very late stent thrombosis (VLST) or late
target-lesion revascularization (TLR) have emerged as new problems after drug-
eluting stent implantation. However, there is a paucity of data from long-term follow-
up studies evaluating late adverse events after sirolimus-eluting stents (SES)
implantation in comparison with bare-metal stent (BMS) implantation.
Methods: Among 13058 consecutive patients undergoing ﬁrst percutaneous coronary
intervention in the CREDO-Kyoto registry Cohort-2, 5078 patients were treated with
SES only and 5392 patients were treated with BMS only. Median follow-up duration
was 1974 (inter-quartile range: 1700-2225) days.
Results: During 4-7 years follow-up after SES implantation, VLST and late TLR
beyond 1-year occurred constantly and without attenuation at 0.24%/year, and 2.0%/
year, respectively. Cumulative 7-year incidence of VLST was signiﬁcantly higher in
the SES group than in the BMS group (1.43% vs. 0.68%, P<0.0001). However, there
was no excess of all-cause death beyond 1-year in the SES group as compared with the
BMS group (20.8% vs. 19.6%, P¼0.91), although the cumulative incidence of sudden
death beyond 1-year was slightly but signiﬁcantly higher in the SES group than in the
BMS group (3.0% vs. 1.8%, P¼0.02). Cumulative 7-year incidences of late TLR and
clinically-driven late TLR were also signiﬁcantly higher in the SES group than in the
BMS group (12.0% vs. 4.1%, P<0.0001 and 8.5% vs. 2.6%, P<0.0001, respectively),
leading to signiﬁcant late catch-up of the SES group to the BMS group regarding the
cumulative incidence of over-all and clinically-driven TLR through 7-year (18.8% vs.
25.2%, and 10.6% vs. 10.2%, respectively). Clinical indication of late TLR in the SES
group included acute myocardial infarction (13.1%), unstable angina (8.1%), stable
angina (34.0%), asymptomatic ischemia (7.9%) and non-clinically driven (36.9%).
Conclusions: During 4-7 years follow-up after SES implantation, late adverse events
including VLST and late TLR continued to occur without attenuation of their inci-
dences. Late catch-up phenomenon of SES relative to BMS in terms of TLR was real
and should be the target for the development of drug-eluting stents.
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Background: Late target lesion revascularization (TLR) and stent thrombosis with
drug-eluting stents (DES) remain a concern, especially in the thrombogenic milieu
of acute coronary syndrome (ACS). This study aims to investigate the long-term
safety and efﬁcacy of everolimus- (EES) and zotarolimus-eluting stents (ZES)B60 JACC Vol 62/18/Suppl B j October 27–November 1, 2013to 1st-generation sirolimus-eluting stents (SES) and bare metal stents (BMS) in ACS
patients.
Methods:We identiﬁed 1612 patients presenting with ACS who received either BMS,
SES, ZES or EES. The primary end points were probable or deﬁnite stent thrombosis
(ST) and major adverse cardiovascular event (MACE) deﬁned as composite of all-
cause death, myocardial infarction, or TLR up to 3 years.
Results: The 3-year MACE was 44.9% in the BMS group versus 34.6% in the SES
group versus 21.8% in the ZES group and 18.5% in the EES group (p <0.001).
Mortality at 3 years was highest in the BMS group (36.7%) than in the SES, ZES or
EES groups (22.5% vs 12.9% vs 12%, respectively; p <0.001). The 30-day ST was
highest in the SES group (5.1%) compared to BMS group (1.4%), ZES group (2.3%)
and EES group (1.1%) (p <0.001).These ﬁndings were reﬂected at 3 years (7.5% vs
1.9% vs 2.3% vs 1.5%, respectively; p <0.001).
Conclusions: The newer drug-eluting stents, EES and ZES, have shown improved
rate of MACE over BMS and 1st-generation SES. In addition, ST rates up to 3 years in
EES and ZES were comparable to BMS in ACS patients.TCT-186
Comparison of 5-year outcomes between drug-eluting and bare-metal stents in
patients after acute myocardial infarction with or without diabetes
Wei-Chun Huang1, Kuan-Rau Chiou2, Feng-Yu Kuo2, Chin-Chang Cheng2,
Cheng-Chung Hung2, Shin-Hung Hsiao3, Jin-Shiou Yang4, Shao-Lin Lin2,
Guang-Yuan Mar2, Chuen-Wang Chiou2, Chun-Peng Liu2
1Cardiovascular Center, Kaohsiung Veterans General Hospital, National Yang-Ming
and Fooyin University, Kaohsiung , Taiwan, 2Cardiovascular Center, Kaohsiung
Veterans General Hospital, Kaohsiung , Taiwan, 3Cardiovascular center, Kaohsiung
Veterans General Hospital, Kaohsiung, Taiwan, 4Department of Physical Therapy,
Fooyin University, Kaohsiung , Taiwan
Background: Patients with acute myocardial infarction (AMI) have had conﬂicting
results between drug-eluting stents (DES) and bare-metal stents (BMS). The aim of
this study was to compare 5-year outcomes between DES and BMS in Asian patients
after AMI with or without diabetes (DM).
Methods: This study enrolled 1137 consecutive AMI patients who received stent
implantation in a single tertiary medical center from 2004 to 2011. The patients were
divided into DES (N¼210, 60 DM patients) and BMS group (N¼927, 302 DM
patients)in the study. The 5-year outcomes were collected, including early thrombosis
events (< 1 month), late thrombosis events (1-12 months), very late thrombosis events
(>12 months), time to the occurrence of myocardial re-infarction and time to
cardiovascular death.
Results: The baseline characteristics and complication rates were not different
between BMS and DES study groups. BMS and DES had almost identical rate of early
thrombosis (0.9% vs 0%, p¼0.117), late thrombosis (2.2% vs 1.0%, p¼0.252) and
very late thrombosis (0.8% vs 0%, p¼0.207). The Kaplan-Meier analysis showed
there was no difference of 5-year myocardial re-infarction event rate and 5-year
cardiovascular survival between DES and BMS groups, whether DM or non-DM
patients (Please see Figure).j TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stent Studies
